{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:58Z","timestamp":1790821558025,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107088","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T16:19:17Z","timestamp":1771690757000},"page":"107088","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the \u201cGA transition\u201d study"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5460-2977","authenticated-orcid":false,"given":"Irene","family":"Schiavetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Annovazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Cordioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Pozzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Signoriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Lus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Pasquali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Laroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cavalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"La Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Torri Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Zecca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Caleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2026.107088_bib0003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s40120-017-0079-3","article-title":"A comprehensive review on copemyl","volume":"6","author":"Annovazzi","year":"2017","journal-title":"Neurol. Ther."},{"issue":"5","key":"10.1016\/j.msard.2026.107088_bib0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/0897190017725984","article-title":"Development of Glatopa (Glatiramer Acetate): the First FDA-approved generic disease-modifying therapy for relapsing forms of multiple sclerosis","volume":"31","author":"Bell","year":"2018","journal-title":"J. Pharm. Pract."},{"issue":"4","key":"10.1016\/j.msard.2026.107088_bib0006","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70140","article-title":"Generics, biosimilars and follow-on non-biologic complex drugs for multiple sclerosis: a narrative review of the regulatory and clinical implications for European neurologists","volume":"32","author":"Berger","year":"2025","journal-title":"Eur. J. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2026.107088_bib0002","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2165\/11204560-000000000-00000","article-title":"Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis","volume":"70","author":"Carter","year":"2010","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.msard.2026.107088_bib0007","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jamaneurol.2015.2154","article-title":"Equivalence of generic glatiramer acetate in multiple sclerosis: a randomized clinical trial","volume":"72","author":"Cohen","year":"2015","journal-title":"JAMA Neurol."},{"issue":"7","key":"10.1016\/j.msard.2026.107088_bib0010","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/03007995.2020.1760808","article-title":"Multiple sclerosis relapse rates and healthcare costs of two versions of glatiramer acetate","volume":"36","author":"Greenberg","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.msard.2026.107088_bib0009","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J. Biomed. Inform."},{"key":"10.1016\/j.msard.2026.107088_bib0004","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejps.2019.03.011","article-title":"Glatiramer acetate: a complex drug beyond biologics","volume":"133","author":"Rocco","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.msard.2026.107088_bib0008","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1177\/1352458516688956","article-title":"Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results","volume":"23","author":"Selmaj","year":"2017","journal-title":"Mult. Scler"},{"issue":"2","key":"10.1016\/j.msard.2026.107088_bib0001","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:18:18Z","timestamp":1781525898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":10,"alternative-id":["S2211034826001240"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107088","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world evaluation of the transition between originator and follow-on glatiramer acetate in people with multiple sclerosis: the \u201cGA transition\u201d study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107088","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107088"}}